NCT04907149View on ClinicalTrials.gov

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

July 12, 2021

Study Completion Date

July 12, 2021

Conditions
Healthy
Interventions
DRUG

GLPG3970 film-coated tablet

Participants will receive a single oral dose of GLPG3970.

DRUG

[14C]GLPG3970 solution for infusion

Participants will receive an i.v. microtracer microdose.

DRUG

[14]GLPG3970 oral solution

Participants will receive a single oral dose \[14C\]GLPG3970.

Trial Locations (1)

NG11 6JS

Quotient Sciences Ltd, Nottingham

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04907149 - Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 | Biotech Hunter | Biotech Hunter